Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;10(2):233-242.
doi: 10.52547/rbmb.10.2.233.

The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV- Genotype 1-B

Hamed Esmaeil Lashgarian  1 , Ali Valibeik  2 , Abdolrazagh Marzban  3 , Maryam Karkhane  2 , Kiana Shahzamani  4
Affiliations

The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV- Genotype 1-B

Hamed Esmaeil Lashgarian et al. Rep Biochem Mol Biol. 2021 Jul.

Abstract

Background: Hepatitis C virus (HCV) is one of the major causes of chronic liver disease, as it holds a significant role in developing liver cirrhosis and hepatocellular carcinoma. Combination therapy with Pegaferon and Ribavirin leads to viral clearance of only 50% of patients. During the host antiviral response, protein kinase R (PKR) interacts with eukaryotic translation initiation factor 2 alpha (eIF2α), that leads to the inhibition of viral protein synthesis. The viral NS5A protein appears to interfere with this antiviral action, evading the host immune response. However, mutations in the NS5A gene have been observed to render HCV more susceptible to treatment. The aim of this study was to determine the mutations present in the IFN Sensitivity Determining Region (ISDR) and NS5A-PKRbinding domain regions in chronic HCV infected patients before and after therapy.

Methods: Viral RNA was isolated from the plasma of 52 chronic HCV infected patients before and after treatment. RT-Nested PCR reaction was used to reverse transcription and amplification of target fragment using the specific primers.

Results: Sequence analysis revealed no relationship between NS5A mutations and response to treatment. No significant difference was found between the mutations before and 3 months after treatment among responders and non-responders.

Conclusion: This study showed that the number of mutations in NS5A did not significantly differ between the patients who responded to treatment and the patients that did not. Therefore, sequencing of these regions does not appear to be a suitable tool for predicting treatment outcomes.

Keywords: Genotype b1; Hepatitis C virus; Mutation; Non-structural protein (NS5A); Response to combination therapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Results of NS5A gene amplification by RT-Nested PCR of the HCV-b1 genotype. A) 100bp DNA marker B to F) patient samples with 744 bp length.
See this image and copyright information in PMC

References

    1. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122, 132. - PubMed
    1. Karkhane M, Mohebbi SR, Azimzadeh P, Niasar MS, Sarbazi MR, Sharifian A, et al. Lack of association between interleukin 28B gene polymorphisms (rs8099917G/T, rs12979860 C/T) and susceptibility to chronic hepatitis C virus infection, Tehran, Iran. Gastroenterol Hepatol Bed Bench. 2016;9(Suppl1):S29, S35. - PMC - PubMed
    1. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353, 63. - PMC - PubMed
    1. Ip PP, Nijman HW, Wilschut J, Daemen T. Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral research. 2012;96(1):36, 50. - PubMed
    1. Bartenschlager R, Lohmann V. The Hepatitis C Virus Replicon System and Its Role in Drug Development. 2019:69–96.

LinkOut - more resources